放疗后复发前列腺癌的非手术挽救性局部治疗:系统综述与Meta分析
该系统综述与Meta分析纳入2000年1月1日至2018年2月1日Medline、Scopus和ClinicalKey数据库的64项病例系列研究、共5585例放疗后前列腺内复发患者,比较近距离放疗(BT)、外照射放疗(EBRT)、高强度聚焦超声(HIFU)和冷冻治疗等非手术挽救性局部治疗的效果与毒性。生化控制率HIFU最低(58%,95%CI 47-68%),BT(69%,95%CI 62-76%)和EBRT(69%,95%CI 53-83%)最高;尿失禁发生率BT最低(3%,95%CI 0-6%;I2=63.4%),HIFU最高(28%,95%CI 19-38%;I2=89.7%)。作者认为非手术挽救性局部治疗尤其是BT在生化控制和耐受性方面表现良好,但需前瞻性试验的高质量数据验证长期结局。
要点
- 64项病例系列研究、5585例放疗后前列腺内复发患者纳入分析。
- 生化控制率HIFU 58%(95%CI 47-68%),BT 69%(95%CI 62-76%),EBRT 69%(95%CI 53-83%)。
- 尿失禁发生率BT 3%(95%CI 0-6%;I2=63.4%),HIFU 28%(95%CI 19-38%;I2=89.7%)。
核心结论
- 非手术挽救性局部治疗尤其是BT在放疗后局部复发患者中生化控制和耐受性表现良好。
- 作者指出需要前瞻性试验的高质量数据来验证非手术策略治疗放疗后前列腺内复发的长期结局。
研究设计与样本
- 系统综述与Meta分析,检索Medline、Scopus和ClinicalKey数据库2000年1月1日至2018年2月1日的文献,遵循PRISMA声明。
- 采用改良Delphi工具评估病例系列研究质量,共纳入64项病例系列研究、5585例患者。
- 改良Delphi清单显示总体方法学质量较高,平均质量评分为80.6%。
主要发现
- 生化控制率HIFU最低(58%,95%CI 47-68%),BT(69%,95%CI 62-76%)和EBRT(69%,95%CI 53-83%)最高。
- 尿失禁发生率BT最低(3%,95%CI 0-6%;I2=63.4%),HIFU最高(28%,95%CI 19-38%;I2=89.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要前瞻性试验的高质量数据来验证非手术策略治疗放疗后前列腺内复发的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control and significant genitourinary toxicity. OBJECTIVE: To conduct a systematic review and meta-analysis of the role of nonsurgical salvage modalities in patients with radiorecurrent prostate cancer and associated clinical outcomes and toxicity profiles. EVIDENCE ACQUISITION: We performed a critical review of the Medline, Scopus, and ClinicalKey databases from January 1, 2000 through February 1, 2018 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool for case-series studies. EVIDENCE SYNTHESIS: A total of 64 case-series studies were included, corresponding to a cohort of 5585 patients. The modified Delphi checklist evidenced high methodological quality overall (mean quality score of 80.6%). Biochemical control rates were lowest for patients treated with HIFU (58%, 95% confidence interval [CI] 47-68%) and highest for patients treated with BT (69%, 95% CI 62-76%) and EBRT (69%, 95% CI 53-83%). The lowest prevalence of incontinence was for patients treated with BT (3%, 95% CI 0-6%; I2=63.4%) and the highest was among patients treated with HIFU (28%, 95% CI 19-38%; I2=89.7%). CONCLUSIONS: Nonsurgical therapeutic options, especially BT, showed good outcomes in terms of biochemical control and tolerability in the local recurrence setting. PATIENT SUMMARY: The current analysis demonstrated that nonsurgical salvage local therapies offer a chance of a curative local approach in radiorecurrent prostate cancer. However, high-quality data from prospective trials are needed to validate long-term outcomes from nonsurgical strategies for the treatment of intraprostatic recurrence after previous radiotherapy.
引用
- Ingrosso G, Becherini C, Lancia A, et al. Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2019. PMID: 31411996. doi:10.1016/j.euo.2018.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。